Brii Biosciences Limited Total Liabilities
Brii Biosciences Limited total liabilities. Based on the latest financial reports, Brii Biosciences Limited (7SS) has total liabilities worth €36.20 Million EUR (≈ $42.32 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Brii Biosciences Limited (7SS) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Brii Biosciences Limited (2020–2025)
Total liabilities of Brii Biosciences Limited from 2020 to 2025. This chart illustrates how Brii Biosciences Limited's total liabilities have evolved over time, based on quarterly financial data.
Brii Biosciences Limited Competitors by Total Liabilities
The table below lists competitors of Brii Biosciences Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shotspotter Inc
NASDAQ:SSTI
|
USA | $63.58 Million |
|
Desa Deri Sanayi ve Ticaret AS
IS:DESA
|
Turkey | TL1.50 Billion |
|
Tropical Canning (Thailand) Public Company Limited
BK:TC
|
Thailand | ฿1.30 Billion |
|
Stella Holdings Bhd
KLSE:5006
|
Malaysia | RM768.44 Million |
|
EDAG Engineering Group AG
XETRA:ED4
|
Germany | €557.07 Million |
|
Vistin Pharma ASA
OL:VISTN
|
Norway | Nkr103.25 Million |
|
Daehan Green Power Corporation
KQ:060900
|
Korea | ₩11.26 Billion |
|
Insumos Agroquimicos SA
BA:INAG
|
Argentina | AR$39.89 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Brii Biosciences Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Brii Biosciences Limited (7SS) total assets.
Liquidity & Leverage Metrics
Brii Biosciences Limited Total Liabilities Ratios Explained
Brii Biosciences Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 60.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Brii Biosciences Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Brii Biosciences Limited (2020–2025)
The table below shows the annual total liabilities of Brii Biosciences Limited from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €36.20 Million ≈ $42.32 Million |
-63.99% |
| 2024-12-31 | €100.55 Million ≈ $117.55 Million |
-20.12% |
| 2023-12-31 | €125.87 Million ≈ $147.15 Million |
-46.29% |
| 2022-12-31 | €234.35 Million ≈ $273.98 Million |
-22.00% |
| 2021-12-31 | €300.44 Million ≈ $351.25 Million |
-90.02% |
| 2020-12-31 | €3.01 Billion ≈ $3.52 Billion |
-- |
About Brii Biosciences Limited
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neut… Read more